公开(公告)号：US12029795B2

公开(公告)日：2024-07-09

申请号：US17918057

申请日：2021-04-09

Applicant: Verve Therapeutics, Inc.

Inventor： Alexandra Chadwick ,  Kallanthottathil G. Rajeev ,  Ellen Rohde ,  Christopher Cheng ,  Caroline Reiss

IPC: C07H21/04 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/46 ,  A61K48/00 ,  C07K14/515 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/90

CPC classification number: A61K48/0066 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/465 ,  C07K14/515 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/907 ,  C07K2319/09 ,  C07K2319/80 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/331 ,  C12N2310/335 ,  C12N2310/344 ,  C12N2310/3521 ,  C12N2800/80

Abstract: Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.

公开(公告)号：US12029755B2

公开(公告)日：2024-07-09

申请号：US17535080

申请日：2021-11-24

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Yogendra Kanthi ,  David J. Pinsky

IPC: A61K33/00 ,  A61K9/00 ,  A61K33/24 ,  A61K45/06 ,  A61L27/02 ,  A61L27/18 ,  A61L27/34 ,  A61L27/54 ,  A61L27/58 ,  A61L29/06 ,  A61L29/16 ,  A61L31/02 ,  A61L31/06 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16 ,  A61P9/00 ,  A61B17/00 ,  A61B17/12 ,  A61F2/01 ,  A61K9/127 ,  A61K9/51 ,  A61M1/16 ,  A61M1/36 ,  A61M60/148

CPC classification number: A61K33/00 ,  A61K9/0073 ,  A61K33/24 ,  A61K45/06 ,  A61L27/025 ,  A61L27/18 ,  A61L27/34 ,  A61L27/54 ,  A61L27/58 ,  A61L29/06 ,  A61L29/16 ,  A61L31/028 ,  A61L31/06 ,  A61L31/10 ,  A61L31/148 ,  A61L31/16 ,  A61P9/00 ,  A61B2017/00575 ,  A61B2017/00893 ,  A61B17/12022 ,  A61B17/12122 ,  A61F2/01 ,  A61K9/0024 ,  A61K9/127 ,  A61K9/5153 ,  A61M1/1698 ,  A61M1/3666 ,  A61M60/148 ,  A61M2202/0233 ,  A61K33/00 ,  A61K2300/00 ,  A61K33/24 ,  A61K2300/00 ,  A61L31/06 ,  C08L67/04 ,  A61L29/06 ,  C08L67/04

Abstract: Disclosed herein are methods of treating venous thrombosis and vascular inflammation through administration of carbon monoxide and/or a carbon monoxide releasing molecule. Also disclosed herein are devices capable of releasing carbon monoxide for the purpose of treating microvascular, arterial and venous thromboembolism and/or inflammation.

公开(公告)号：US20240200046A1

公开(公告)日：2024-06-20

申请号：US18556593

申请日：2022-04-22

Applicant: Precision BioSciences, Inc. ,  NORTH CAROLINA STATE UNIVERSITY

Inventor： Carlos T. Moraes ,  James Jefferson Smith ,  Derek Jantz ,  Ginger H. Tomberlin ,  John Morris ,  Wendy Shoop

IPC: C12N9/22 ,  A61K9/127 ,  A61K38/46 ,  A61K48/00 ,  C12N15/86

CPC classification number: C12N9/22 ,  A61K9/127 ,  A61K38/465 ,  A61K48/005 ,  C12N15/86 ,  C07K2319/07 ,  C12N2750/14143

Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in combination with mitochondrial transit peptides in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been modified or edited.

公开(公告)号：US20240197765A1

公开(公告)日：2024-06-20

申请号：US18556171

申请日：2021-05-13

Applicant: BIONEXT LABS LTD

Inventor： Michael Shlomo Bernstein

IPC: A61K31/7056 ,  A61K9/127 ,  A61K35/644 ,  A61K36/185 ,  A61K36/282 ,  A61K36/53 ,  A61K36/537 ,  A61K36/61 ,  A61K36/63 ,  A61K36/8962 ,  A61K36/9066 ,  A61K47/10 ,  A61K47/24

CPC classification number: A61K31/7056 ,  A61K9/127 ,  A61K35/644 ,  A61K36/185 ,  A61K36/282 ,  A61K36/53 ,  A61K36/537 ,  A61K36/61 ,  A61K36/63 ,  A61K36/8962 ,  A61K36/9066 ,  A61K47/10 ,  A61K47/24

Abstract: Antiviral liposomal compositions comprising ascorbyl 2-glucoside (AA2G) and other active ingredients including propolis extract and other natural plant extracts, use thereof as an effective medicament, prophylactic, or nutritional supplement against viral infections in general and for treating and or preventing coronavirus disease 2019 (COVID-19) in particular, and methods of preparing such antiviral compositions.

公开(公告)号：US12012601B2

公开(公告)日：2024-06-18

申请号：US17150151

申请日：2021-01-15

Applicant: Bio-Path Holdings, Inc.

Inventor： Ana Tari Ashizawa

IPC: C12N15/113 ,  A61K9/00 ,  A61K9/127 ,  A61K31/506 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7088 ,  A61P35/02 ,  C12Q1/68

CPC classification number: C12N15/1138 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/506 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7088 ,  A61P35/02 ,  C12N2310/11 ,  C12N2310/31 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2320/35

Abstract: Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine). The cancer may be Ph+ and/or Bcr-Abl positive chronic myelogenous leukemia or acute myeloid leukemia or myelodysplastic syndrome.

公开(公告)号：US12005146B2

公开(公告)日：2024-06-11

申请号：US18126251

申请日：2023-03-24

Applicant: THERASYN SENSORS, INC

Inventor： Jerome J. Schentag ,  Mary P. McCourt ,  Lawrence Mielnicki ,  Julie Hughes

IPC: A61K9/51 ,  A61K9/127 ,  A61K31/12 ,  A61K31/137 ,  A61K31/19 ,  A61K31/546 ,  A61K31/7034 ,  A61K31/713 ,  A61K38/14 ,  A61K38/28 ,  A61K39/29 ,  A61K39/395 ,  A61K45/06

CPC classification number: A61K9/51 ,  A61K9/127 ,  A61K9/1275 ,  A61K31/12 ,  A61K31/137 ,  A61K31/19 ,  A61K31/546 ,  A61K31/7034 ,  A61K31/713 ,  A61K38/14 ,  A61K38/28 ,  A61K39/29 ,  A61K39/3955 ,  A61K45/06

Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

公开(公告)号：US12005102B2

公开(公告)日：2024-06-11

申请号：US17091553

申请日：2020-11-06

Applicant: AC Immune SA

Inventor： Emma Fiorini ,  Marija Vukicevic Verhille ,  Maria Pihlgren Bosch

IPC: A61K39/395 ,  A61K9/127 ,  A61K39/00 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005

CPC classification number: A61K39/0007 ,  A61K9/127 ,  A61K39/0003 ,  A61K39/0005 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/58 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/33 ,  C07K2319/55 ,  C12N2710/16232 ,  C12N2710/16234 ,  C12N2760/16033

Abstract: A liposomal vaccine composition comprises a β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.

公开(公告)号：US20240180868A1

公开(公告)日：2024-06-06

申请号：US17797771

申请日：2022-04-08

Applicant: QVET

Inventor： Juyeon SONG

IPC: A61K31/352 ,  A61K9/00 ,  A61K9/127 ,  A61P31/14 ,  A61P31/20

CPC classification number: A61K31/352 ,  A61K9/0043 ,  A61K9/127 ,  A61P31/14 ,  A61P31/20

Abstract: The present disclosure relates to a pharmaceutical composition comprising rottlerin as an active ingredient for the prevention or treatment of a virus infection. The pharmaceutical composition of the present disclosure for the prevention or treatment of a virus infection comprising rottlerin as an active ingredient can be advantageously used to treat a virus infection caused by coronavirus, porcine epidemic diarrhea virus, transmissible gastroenteritis virus, porcine circovirus type 2, porcine reproductive and respiratory syndrome virus, or the like.

公开(公告)号：US20240180825A1

公开(公告)日：2024-06-06

申请号：US18285315

申请日：2022-04-19

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： Santiago Correa ,  John Klich ,  Eric Andrew Appel

IPC: A61K9/06 ,  A61K9/00 ,  A61K9/127 ,  A61K47/38

CPC classification number: A61K9/06 ,  A61K9/0019 ,  A61K9/127 ,  A61K47/38

Abstract: An injectable hydrogel network is provided distinguishing a non-covalently cross-linked hydrogel network with polymers functionalized with hydrophobic fatty pendant groups hydrophobically cross-linked with liposomal nanoparticles in which the liposomal nanoparticles are the cross-linkers. As the hydrogel is injectable, it is easily administered under the skin and does not require invasive surgical implantation. After injection the hydrogel rapidly self-heals to form a robust solid-like depot that can persist in the body over relevant timescales. The material does not cause a negative immune response like many other materials do. The hydrogel can gradually degrade over time in the body and therefore would not require surgical removal. Different embodiments modifying the surface chemistry of the liposomes give this hydrogel the ability to release therapeutic cargo, such as proteins, over controlled programmable timescales regardless of cargo size because the material can interact with the cargo through electrostatic or affinity interactions.

公开(公告)号：US11998571B2

公开(公告)日：2024-06-04

申请号：US18046719

申请日：2022-10-14

Applicant: DESIGNED CELLS CO., LTD.

Inventor： Yun Bae Kim ,  Ehn Kyoung Choi ,  Tae Myoung Kim

IPC: A61K35/50 ,  A23L33/10 ,  A61K9/127 ,  A61P27/02 ,  A61P27/06 ,  C12N5/073

CPC classification number: A61K35/50 ,  A23L33/10 ,  A61K9/127 ,  A61P27/02 ,  A61P27/06 ,  C12N5/0605 ,  A23V2002/00 ,  C12N2500/02

Abstract: Disclosed herein is a pharmaceutical composition comprising at least one selected from the group consisting of a stem cell-conditioned medium and an exosome isolated therefrom as an active ingredient for prevention or treatment of an ocular disease. Containing exosomes, growth factors and neurotrophic factors at high levels and functioning to: promote retinal cell proliferation and wound recovery; protect retinal cells against oxidative stress or hypoxia; lower the increased intraocular pressure and restore the atrophy of the retinal layer and the retinal ganglion cell layer to normal levels in the glaucoma animal model; and have a protective effect on retinal ganglion cells and nerve cells, the stem cell-conditioned medium according to the present disclosure can find advantageous applications in the therapy of an ocular disease.